Provided is the use of a mono- or di- aminopyridine in the manufacture of a medicament for the treatment of impairments in gait or balance in patients with multiple sclerosis. A preferred aminopyridine is 4-aminopyridine, also known as dalfampridine. In a preferred embodiment there is provided a use of an aminopyridine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an impairment in postural balance or an impairment in balance assayable by the Berg Balance Scale in a human patient with multiple sclerosis, wherein the medicament comprises the aminopyridine or pharmaceutically acceptable salt thereof in an amount in the range of 5 to 20 mg in a sustained release composition, wherein the patient has been diagnosed with an impairment in balance, and wherein the treating comprises orally administering the sustained release composition once or twice daily, wherein the aminopyridine is a mono- or di- aminopyridine.
